focus -WSS

focus

author：comprehensive 2025-10-01 22:59:20 - browse：56915

Adam's take main illustration — Molly Ferguson/STAT

It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage clinical trial in Rett syndrome.

The negative study outcome was never in doubt, so the only surprise from Tuesday’s announcement was the company’s lame attempt at damage control. Anavex is a serial dissembler of clinical trial results, so I was expecting better spin. Instead, management barely tried, which tells you the real results from the Rett study must be truly awful.

Anavex shares fell 31% to $6 in early trading. The company’s only drug in clinical development, called blarcamesine, is a zero. Rett is the latest failure, following earlier study failures in Alzheimer’s disease and Parkinson’s disease. Yet even with Tuesday’s drop in share price, Anavex still carries a fully diluted market value of nearly $650 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： Stopping antidepressants leads to symptoms for 1 in 6 patients

explore

hotspot

WSS

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

ASCO Takeaways: Winners, snoozers, and the art of cancer care

FDA approves Moderna’s RSV vaccine, its second licensed product

Obesity experts on risks of Wegovy, Ozempic weight loss drugs

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

New guidelines on severe brain injury complicate already difficult decisions

leisure time

focus

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

How CO2 helps viruses stay alive longer in the air

In Memoriam: Notable people who died in 2023

Donald Trump's relentless attacks on special counsel Jack Smith

Duchenne breakthrough therapy leaves behind pioneering families

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Hepatitis C has a cure — but many Americans still lack access to it

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

Medicare proposal to cover medical devices draws a mixed reaction

Paxlovid study fails to answer questions over benefit for broader groups

focus

CMS got Medicare Advantage quality rating wrong, judge rules

WATCH: Why do fingernails fall off when they're damaged?

Illumina board agrees to spin off Grail, as divestment plans proceed

ASCO Daily Recap: CAR

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Paxlovid study fails to answer questions over benefit for broader groups

Wikipedia

explore

hotspot

hotspot